Esperion Therapeutics | ESPR - Nettoeinkommen

Aktienkurs
2.59
Täglich Wechseln
0.04 1.37%
Monatlich
-22.60%
Jährlich
52.96%
Q1 Prognose
2.47




Nettoeinkommen Veränderung Datum
AbbVie USD 1.82B 1.63B 2025-12
Alnylam Pharmaceuticals USD 186.42M 64.66M 2025-12
Alterity Therapeutics Limited AUD -5.77M 2.26M 2023-06
Amarin USD -1.22M 6.51M 2025-12
Amgen USD 1.33B 1.88B 2025-12
Biogen USD 466.5M 168.3M 2025-09
BioMarin Pharmaceutical USD -46.57M 15.83M 2025-12
Cipla INR 6.76B 6.75B 2025-12
CSL USD 401M 96.5M 2025-12
Cytokinetics USD -183.03M 123.15M 2025-12
Daiichi Sankyo JPY 86.63B 41.32B 2025-12
Eli Lilly USD 6.64B 1.05B 2025-12
Esperion Therapeutics USD 61.83M 93.16M 2025-12
Geron USD -31.14M 12.72M 2025-12
Grifols EUR 114.37M 34.03M 2025-12
Halozyme Therapeutics USD -141.59M 316.82M 2025-12
Heron Therapeutics USD -2.95M 14.54M 2025-12
Ionis Pharmaceuticals USD -229M 100.39M 2025-12
Merck USD 2.96B 2.82B 2025-12
Minerva Neurosciences USD 1.44M 21.07M 2024-12
Moderna USD -200M 625M 2025-09
Nektar Therapeutics USD -37.06M 15.31M 2024-09
Pfizer USD -1.65B 5.19B 2025-12
PTC Therapeutics USD -134.96M 150.86M 2025-12
Puma Biotechnology USD 20.32M 24.85M 2024-09
Regeneron Pharmaceuticals USD 844.6M 615.4M 2025-12
Sanofi EUR -801M 3.6B 2025-12
Sarepta Therapeutics USD -412.23M 232.28M 2025-12
United Therapeutics USD 364.3M 25.6M 2025-12
Vanda Pharmaceuticals USD -18.9M 13.58M 2024-12